Johnson & Johnson secured FDA approval for Icotyde (icotrokinra), the first oral IL-23 receptor antagonist for moderate-to-severe plaque psoriasis—a massive first-in-class mechanism in a pill.

Gossamer Bio (GOSS) is cutting 48% of its workforce after seralutinib's Phase 3 PAH trial missed its primary endpoint. The stock has cratered 80% since the readout.

Rhythm (RYTM) faces its highly anticipated Imcivree PDUFA for acquired hypothalamic obesity tomorrow.

Correction: The FDA pushed Eli Lilly's orforglipron target action date to April 10, not late March as previously reported. Yesterday's email referenced older analyst estimates that have since been updated.

Rhythm PDUFA (Tomorrow, March 20): Imcivree sNDA decision for acquired hypothalamic obesity. Phase 3 TRANSCEND data was strong (16.4% BMI reduction vs. placebo, p<0.0001), no new data was requested, and no safety/manufacturing flags were raised.

Orforglipron (Updated Timeline): The FDA has pushed the target action date to April 10. Lilly CEO David Ricks confirmed a Q2 2026 expected decision at JPM in January; this correction reflects the most current reporting from Reuters and BioSpace.

GTC Final Day (Today): Student and Community Day wraps NVIDIA GTC. Healthcare sessions from Wednesday are worth reviewing for BioNeMo and Nemotron open model announcements.

Rocket Pharma (March 28): Kresladi PDUFA for LAD-I gene therapy remains the next major decision after Rhythm.

What Happened: The FDA approved Johnson & Johnson's Icotyde (icotrokinra), the first and only oral peptide that selectively blocks the IL-23 receptor, for moderate-to-severe plaque psoriasis in adults and patients 12+ weighing at least 40 kg.

The Deal: The drug was co-developed with Protagonist Therapeutics (PTGX), which triggered a $50 million milestone payment and is eligible for 6-10% royalties on sales plus up to $580 million in future milestones.

The Data: The ICONIC Phase 3 program spanned four studies and ~2,500 patients. In head-to-head superiority trials (ICONIC-ADVANCE 1 and 2), ~70% of patients achieved clear or almost clear skin (IGA 0/1) and 55% hit PASI 90 at Week 16. Icotyde beat Bristol Myers Squibb's Sotyktu (deucravacitinib) on skin clearance at both Weeks 16 and 24. Safety was within 1.1% of placebo through Week 16, with no new signals through 52 weeks.

Executive Impact: This is a genuine inflection point for oral systemic treatment in dermatology. IL-23 pathway blockade has been the gold standard in psoriasis, but until today required injectable biologics (Tremfya, Skyrizi, Stelara). BMS's Sotyktu ($291M in 2025 sales) now faces a direct oral competitor with a stronger mechanism.

The Setup: Rhythm's (RYTM) March 20 PDUFA for Imcivree in acquired hypothalamic obesity is less than 24 hours away. The TRANSCEND Phase 3 data showed 16.4% mean BMI reduction vs. a 2.4% increase on placebo.

The Context: Responder rates were highly impressive: 80% at >5% BMI reduction, 60% at >10%. The FDA's November extension was for sensitivity analyses only, with no new clinical data requested.

What's at Stake: This would be Imcivree's fourth approved indication and would meaningfully expand Rhythm's addressable market to an estimated 25,000–28,000 patients globally. The sales force is already scaled (42 reps), and the drug generated $194M in 2025 revenue (+50% YoY).

What Happened: Gossamer Bio (GOSS) is cutting 48% of its workforce (~77 roles) and evaluating "strategic options" after the Phase 3 PROSERA trial of seralutinib in pulmonary arterial hypertension (PAH) missed its primary endpoint.

The Data: The 6-minute walk distance improved by 13.3 meters over placebo, which trended in the right direction but failed to reach the prespecified statistical threshold (p=0.0320 vs. required p<0.025).

The Context: Gossamer is pausing enrollment in the Phase 3 SERANATA study in PH-ILD and plans to request a Type C meeting with the FDA by June 2026. Management is pointing to subgroup data in higher-risk patients (20-meter improvement) as a path forward, but with ~$105M in cash expected at the end of Q1 and no other major pipeline assets, options are narrowing fast.

What Happened: Wednesday's GTC sessions focused heavily on healthcare and life sciences applications. NVIDIA highlighted its Nemotron open models and NeMo framework as tools for clinicians and researchers to build customized digital health agents on their own infrastructure.

The Tools: The BioNeMo platform was showcased with new genomics workflow tools, including Parabricks and CUDA-X for large-scale single-cell and CRISPR perturbation analysis.

Executive Impact: The open-source angle is the most meaningful development here. By releasing Nemotron weights and NeMo recipes, NVIDIA is giving pharma and health systems the ability to fine-tune models for medical vocabulary without depending on closed, expensive systems. This could aggressively accelerate adoption in clinical decision support and drug target validation.